Sangui BioTech:
- Revenues of USD 54,000 in the first half-year;
- Granulox license income increased by 54%.

Witten, January 19, 2018,

According to preliminary unaudited figures, Sangui BioTech International Inc. achieved revenues in the amount of approximately USD 54,000 from license fees in the first half year of fiscal 2018 (as of December 31, 2017). Due to increased revenues of the wound spray Granulox, the resulting licensing income in the first half year increased by 54% compared to the same period of the previous year. It is gratifying that not only a strong year-end business contributed to this development. Rather, sales in all four quarters of the 2017 calendar year were significantly higher than in the previous year.

"On the one hand, the positive development in 2017 is based on the fact that our distribution partners can increasingly establish Granulox in their markets. In more and more territories, the frequency and the level of orders show that Granulox can gain a foothold in the respective markets. For example, the successes of our Dutch partners can be cited here. Since obtaining reimbursement in 2016, volumes sold in the Netherlands have significantly exceeded those originally planned. On the other hand, the cooperation entered into with the Zuellig Group for Southeast Asia in mid-2016 is extremely gratifying. We are excited about the professionalism with which our Asian partners approach this project. This concerns both their approval strategy for the individual states as well as the respective marketing and sales concepts, which were implemented as planned in 2017. For 2018, the market launch of Granulox in the first Asian countries is planned. This will further increase the volume of business achieved with Zuellig. Due to these developments, we expect to see a significant increase in total sales of Granulox for the calendar year 2018 ", explains Michael Sander, Managing Director of SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.